Expression of matrix metalloproteinases and their inhibitors in medulloblastomas and their prognostic relevance

Clinical Cancer Research

Volumn 10, Issue 14, 2004, Pages 4746-4753

  Özen, Özlem ^a   Krebs, Bjarne ^a   Hemmerlein, Bernhard ^b   Pekrun, Arnulf ^b   Kretzschmar, Hans ^a   Herms, Jochen ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; MEMBRANE TYPE 2 MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CHILD; CORRELATION ANALYSIS; ENZYME LOCALIZATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; LOGISTIC MODELS; MALE; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; MEDULLOBLASTOMA; METALLOENDOPEPTIDASES; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; SURVIVAL ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 3242666000     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0625-03     Document Type: Article

References (44)

1. David KM, Casey AT, Hayward RD, Harkness WF, Phipps K, Wade AM. Medulloblastoma: is the 5-year survival rate improving? A review of 80 cases from a single institution. J Neurosurg 1997;86:13-21.
2. Kunschner LJ, Kuttesch J, Hess K, Yung WK. Survival and recurrence factors in adult medulloblastoma: the M.D. Anderson Cancer Center experience from 1978 to 1998. Neurooncology 2001;3:167-73.
3. Albright AL, Wisoff JH, Zeltzer PM, Boyett JM, Rorke LB, Stanley P. Effects of medulloblastoma resections on outcome in children: a report from the Children's Cancer Group. Neurosurgery 1996;38:265-71.
4. Miralbell R, Bieri S, Huguenin P, et al. Prognostic value of cerebrospinal fluid cytology in pediatric medulloblastoma. Swiss Pediatric Oncology Group. Ann Oncol 1999;10:239-41.
5. Kedar A. Chemotherapy for pediatric brain tumors. Semin Pediatr Neurol 1997;4:320-32.
6. Romanic AM, Madri JA. Extracellular matrix-degrading proteinases in the nervous system. Brain Pathol 1994;4:145-56.
7. Wright JW, Kramar EA, Meighan SE, Harding JW. Extracellular matrix molecules, long term potentiation, memory consolidation and brain angiotensin system. Peptides 2002;221-46.
8. Rooprai HK, McCormick D. Proteases and their inhibitors in human brain tumours: a review. Anticancer Res 1997;17:4151-62.
9. Arnold SM, Young AB, Munn RK, Patchell RA, Nanayakkara N, Markesbery WR. Expression of p53, bcl-2, E-cadherin, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in paired primary tumors and brain metastasis. Clin Cancer Res 1999;5:4028-33.
10. Beliveau R, Delbecchi L, Beaulieu E, et al. Expression of matrix metalloproteinases and their inhibitors in human brain tumors. Ann N Y Acad Sci 1999;886:236-9.
11. Kachra Z, Beaulieu E, Delbecchi L, et al. Expression of matrix metalloproteinases and their inhibitors in human brain tumors. Clin Exp Methods 1999;17:555-66.
12. Nakagawa T, Kubota T, Kabuto M, et al. Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J Neurosurg 1994;81:69-77.
13. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003;3:489-501.
14. Ribatti D, Surico G, Vacca A, et al. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with progression in human neuroblastoma. Life Sci 2001;68:1161-8.
15. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516.
16. Groft LL, Muzik H, Rewcastle NB, et al. Differential expression and localization of TIMP-1 and TIMP-4 in human gliomas. Br J Cancer 2001;85:55-63.
17. Pagenstecher A, Wussler E, Opdenakker G, Volk B, Campbell IL. Distinct expression patterns and levels of enzymatic activity of matrix metalloproteinases and their inhibitors in primary brain tumors. J Neuropathol Exp Neurol 2001;60:598-612.
18. Nakada M, Kita D, Futami K, et al. Roles of membrane type 1 matrix metalloproteinase and tissue inhibitor of metalloproteinases-2 in invasion and dissemination of human malignant glioma. J Neurosurg 2001;94:464-73.
19. Planchenault T, Costa S, Fages C, et al. Differential expression of laminin and fibronectin and of their related metalloproteinases in human glioma cell lines: relation to invasion. Neurosci Lett 2001;299:140-4.
20. Yong VW, Craig AK, Forsyth PA, Bell R, Edwards DR. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 1998;21:75-80.
21. Forsyth PA, Wong H, Laing TD, et al. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 1999;79:1828-35.
22. Lampert K, Machein U, Machein MR, Conca W, Peter HH, Volk B. Expression of matrix metalloproteinases and tissue inhibitors in human brain tumors. Am J Pathol 1998;153:429-37.
23. Belien ATJ, Paganetti PA, Schwab ME. Membrane-type 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter. J Cell Biol 1999;144:373-84.
24. Choe G, Park JK, Jouben-Steele L, et al. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res 2002;8:2894-901.
25. Nakada M, Nakamura H, Ikeda E, et al. Expression and tissue localization membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. Am J Pathol 1999;154:417-28.
26. Bodey B, Bodey B. Jr, Siegel, SE, Kaiser, HE. Matrix metalloproteinase expression in childhood medulloblastomas/primitive neuroectodermal tumors. In Vivo 2000;14:667-73.
27. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Significant differences in the matrix metalloproteinase expression profiles of spontaneous medulloblastomas/primitive neuroectodermal tumors as compared with their xenografted, established tumor cell line derived counterparts. In Vivo 2000;14:675-82.
28. Rossi M, Rooprai HK, Maidment SL, Rucklige GJ, Pilkington GJ. The influence of sequential, in vitro passage on secretion of matrix metalloproteinases by human brain tumour cells. Anticancer Res 1996;16:121-8.
29. Vince HG, Herbold C, Klein R, et al. Medulloblastoma displays distinct regional matrix metalloprotease expression. J Neurooncol 2001;53:99-106.
30. Kleihues P, Cavenee WK. Tumors of the nervous system. Pathology and genetics. Lyon, France: IARC Press, 2000.
31. Giangaspero F, Bigner SH, Kleihues P, Pietsch T, Trojanowski JQ. Medulloblastoma. In: Kleihues P, Cavenee WK, editors. Pathology and genetics of tumours of the nervous system. Lyon, France: IARC Press, 2000. pp. 129-37.
32. Kuhl J, Muller HL, Berthold F, et al. Preradiation chemotherapy of children and young adults with malignant brain tumors: results of the German pilot trial HIT'88/'89. Klin Padiatr 1998;210:227-33.
33. Bailey CC, Gnekow A, Wellek S, J et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med Pediatr Oncol 1995;25:166-78.
34. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
35. Chang CH, Housepian EM, Herbert CJ. An operative staging system and a megavoltage radiotherapeutic technique for cerebellar medulloblastoma. Radiology 1969;93:1351-9.
36. Rao JS, Yamamoto M, Mohanam S, et al. Expression and localization of 92 kDa type IV collagenase B (MMP-9) in human gliomas. Clin Exp Metastasis 1996;14:12-8.
37. Nakano A, Tani E, Miyazaki K, Yamamoto Y, Furuyama J. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. J Neurosurg 1995;83:298-307.
38. Herms J, Neidt I, Lüscher B, et al. C-myc expression in medulloblastoma and its prognostic value. Int J Cancer 2000;89:395-402.
39. Grotzer MA, Hogarty MD, Janss AJ, et al. messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 2001;7:2425-33.
40. Grotzer MA, Janss AJ, Fung K, et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol 2000;18:1027-35.
41. Gajjar A, Hernan R, Kocak M, et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 2004;22:984-93.
42. Herms J, Behnke J, Bergmann M, et al. Potential prognostic value of C-erbB-2 expression in medulloblastoma in very young children. J Pediatr Hematol Oncol 1997;19:510-5.
43. Munaut C, Noel A, Hougrand O, Foidart, J-M, Boniver J, Deprez M. Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastoma. Int J Cancer 2003;106:848-55.
44. Yoshida D, Watanabe, Noha M, Takahashi H, Teramoto A, Sugisaki Y. Anti-invasive effect of an anti-matrix metalloproteinase agent in a murine brain slice model using the serial monitoring of green fluorescent protein-labeled glioma cells. Neurosurgery 2003;52:187-96.